Evidence map›Paper›PMID 42890846›Full record

ArticleFrontiers in pediatrics2026

Zhiyong Liao, Xiaomei Zou, Jing Liang, Meimei Lai, Qin Wang, Shuzhe Yang, Yao Deng, Chenggui Liu, Weijun He

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhiyong Liao *Department of Clinical Laboratory, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Xiaomei Zou *Department of Clinical Laboratory, Simaqiao Caojiaxiang Community Health Service Center, Chengdu, Sichuan, China.
Jing LiangDepartment of Performance appraisal management, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Meimei LaiDepartment of Clinical Laboratory, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Qin WangDepartment of Clinical Laboratory, Sichuan Province Orthopedic Hospital, Chengdu, China.
Shuzhe YangDepartment of Clinical Laboratory, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Yao DengDepartment of Clinical Laboratory, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Chenggui LiuDepartment of Clinical Laboratory, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Weijun HeDepartment of Clinical Laboratory, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: A retrospective cross-sectional study was conducted at a single center in Chengdu, China, involving children aged 0-18 years who underwent MP polymerase chain reaction (PCR) testing based on clinician requisition or self-requested laboratory testing (SRLT) between January 1 and December 31, 2024. Results: Among 94,889 children (51,105 males and 43,784 females), the overall MP positivity rate was 12.3%, with no significant difference between sexes. Across five clinical diagnostic groups, MP positivity rate was highest in the acute lower respiratory tract infections (ALRTIs) group (13.9%), followed by the SRLT group (12.8%); both were significantly higher than those in the chronic respiratory diseases (CRDs) group (8.8%), the acute upper respiratory tract infections (AURTIs) group (6.6%), and the non-respiratory diseases (NRDs) group (4.8%). MP positivity rates in the ALRTIs, AURTIs, NRDs, and SRLT groups showed significant seasonal variation, peaking in winter, followed by spring; both seasons exhibited significantly higher positivity rates than summer and autumn. Monthly MP positivity rate peaked in January and February across all groups, after which it generally decreased with mild fluctuations, with the ALRTIs group consistently exhibiting the highest positivity rate. Among children with ALRTIs and AURTIs, MP positivity rates were significantly higher in school-aged, preschool, and adolescent children than in toddlers, infants, and newborns ( Conclusions: Among children in Chengdu in 2024, MP PCR positivity peaked in winter (January-February) and was highest in school-aged children. These single-year findings may help inform local surveillance and guide future long-term epidemiological monitoring.

Indexed as

childrenepidemiological characteristicsMycoplasma pneumoniaepolymerase chain reactionpositivity raterespiratory tract infections

Identifiers

PMID42890846
PMCPMC13672482

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.